The Heller School for Social Policy and Management, Brandeis University, Boston, Massachusetts, USA.
Division of Hematology/Oncology, Department of Medicine, Tufts Medical Center, Tufts University, Boston, Massachusetts, USA.
Cancer. 2020 Aug 1;126(15):3417-3425. doi: 10.1002/cncr.32976. Epub 2020 Jun 2.
High out-of-pocket costs (OOPCs) often are found to be inversely associated with adherence to medical treatment. The introduction of generic aromatase inhibitors (GAIs) significantly reduced the OOPCs of patients. The objective of the current study was to explore the impact of the introduction of GAIs on adjuvant hormone therapy (AHT) adherence over the full course of breast cancer treatment.
Women aged ≥65 years who were diagnosed with hormone receptor-positive breast cancer from 2007 through mid-2009 were identified from the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. Multivariate logistic regression was used to estimate the likelihood of AHT initiation and an interrupted time series model was used to predict the association between the introduction of GAIs and AHT adherence. The model was stratified further using Medicare low-income subsidy (LIS) status.
A total of 10,905 women were included, approximately 62.8% of whom initiated AHT within the first year of their breast cancer diagnosis. Adjusted adherence among LIS beneficiaries was 11.4% higher than among non-LIS beneficiaries (P < .001). Non-LIS beneficiaries had an overall decreasing trend of adherence (-0.035; P < .001) prior to the introduction of GAIs. They experienced a 3.4% increase in the slope 6 months after the first GAI, anastrozole, entered the market, and an additional 0.8% increase in the slope 6 months after letrozole and exemestane were introduced (P < .001). Adherence change among LIS patients was small and statistically insignificant.
With the introduction of GAIs, the decrease trend of adherence to therapy atteunated over the course of treatment. Although the successful implementation of the Medicare LIS program minimized the OOPCs for financially vulnerable patients, policymakers should be cautious not to introduce disparities for those who may be of low income but ineligible for such a program.
高自付费用(OOPCs)通常与对治疗的依从性呈反比。通用芳香酶抑制剂(GAIs)的引入显著降低了患者的 OOPC。本研究的目的是探讨 GAIs 的引入对辅助激素治疗(AHT)在整个乳腺癌治疗过程中的依从性的影响。
从监测、流行病学和最终结果(SEER)-医疗保险关联数据库中确定了 2007 年至 2009 年中期诊断为激素受体阳性乳腺癌的年龄≥65 岁的女性。使用多变量逻辑回归估计 AHT 起始的可能性,并使用中断时间序列模型预测 GAIs 的引入与 AHT 依从性之间的关联。该模型进一步按医疗保险低收入补贴(LIS)状况进行分层。
共纳入 10905 名女性,其中约 62.8%在乳腺癌诊断后的第一年开始接受 AHT。LIS 受益人的调整后依从性比非 LIS 受益人高 11.4%(P<.001)。在 GAIs 引入之前,非 LIS 受益人的依从性呈总体下降趋势(-0.035;P<.001)。在第一个 GAIs,阿那曲唑上市后 6 个月,斜率增加了 3.4%,在来曲唑和依西美坦上市后 6 个月,斜率又增加了 0.8%(P<.001)。LIS 患者的依从性变化较小且无统计学意义。
随着 GAIs 的引入,治疗过程中的依从性下降趋势有所缓解。尽管医疗保险 LIS 计划的成功实施使经济脆弱患者的 OOPC 最小化,但政策制定者应谨慎行事,不要为那些可能收入较低但不符合该计划的人引入差距。